You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Table TDI-23. Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2005: the combination of opioids, cocaine, cannabis or other stimulants as primary drug type with a secondary drug [see all tables in this series...]

Part (v) All clients with stimulants other than cocaine as primary drug type: number of episodes reporting the stated drugs as secondary

Country	Opioids	Cocaine	Other stimulants	Hypnotics/sedatives	Hallucinogens	Volatile substances	Cannabis	Alcohol	Others	Total
Bulgaria	1						4			5
Czech Republic	103	8	40	12	29	26	384	39	5	646
Denmark	3	5	15	5	0	1	42	0	201	272
Germany	268	706	3875	130	440	21	1608	847	67	7962
Ireland	3	48	42	6	4	0	76	55	0	234
Greece	1	1	0	0	2	0	2	0	0	6
France	16	26	10	5	14	2	42	11	3	129
Italy	18	118	0	0	40	6	86	13	12	293
Cyprus	3	5	1				2			11
Malta	1	3	0		1		4			9
Netherlands	9	75	96	11	7	0	144	79	9	430
Slovakia	30	21	31	5	13	10	118	37	1	266
Finland	70	1	25	56	1					153
United Kingdom	190	364	352	155	49	12	945	633	28	2728
Total	716	1381	4487	385	600	78	3457	1714	326	13144

Notes:

Data on secondary drug use are only collected among all treatment clients and not separately for new treatment clients.

Opioids' include: heroin, methadone, other opioids; 'Cocaine' includes: cocaine HCl, crack cocaine; 'Stimulants' include: amphetamines, MDMA and derivates, other stimulants: 'Cannabis' can include herb or resin. For each client up to four secondary drugs can be reported.

A number of the clients report using the same drug both as primary and secondary drug, particularly for cannabis. Clients may report using different sub-types of the same substance, as defined in the TDI protocol for the drugs categories.

See also 'General notes for interpreting data' on the Explanatory notes and help page.

Sources:

2006 Reitox national reports.